← Browse by Condition
Medical Condition

unresectable triple negative breast carcinoma

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 1
NCT05673200 Phase 1
Recruiting

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Enrollment
32 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →